Top 25 Immunotherapy venture capital companies based in the United Kingdom

“Autolus is a CAR T cell therapy company.”

“Allergy Therapeutics is a visionary immunology business with specialist experience in the research and development of allergy treatments.”

“An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions.”

“Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients…”

“Achilles Therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells.”

“T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science.”

“Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO)…”

“Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer.”

“Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation.”

“Gylden is a clinical-stage, privately held biotechnology company, headquartered in Abingdon, Oxfordshire, UK, with R&D and GMP manufacturing facilities in Milton Park…”

“Infinitopes is a pioneer in precision immunomics medicines.”

“TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing…”

“Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer.”

“Centauri Therapeutics Limited is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases.”

“Yellowstone aims to unlock a new class of therapeutically targetable frequently expressed antigens with potential to significantly transform patient lives.”

“Leucid is progressing novel CAR T therapies that produce a better and more durable response than previous CAR T generations, improving treatment outcomes and saving the lives of…”

“LIFT BioSciences is pioneering a new class of immunotherapy for hard-to-treat cancers based on allogeneic Immuno-Modulatory Alpha Neutrophils (IMANs)®.”

“Prokarium is pioneering the field of microbial immunotherapy.”

“Broadening cancer patient access to powerful disease-transforming immunotherapy.”

“Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics.”

“Cumulus Oncology is developing anti-cancer therapies for clinical settings in areas of high unmet need, with the aim of developing improved outcomes for cancer patients.”

“4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector.”